ImmunocoreReviews First Quarter2022 Monetary Outcomesand Supplies Enterprise Replace KIMMTRAK® (tebentafusp-tebn) authorised in the US and European Union for the therapy of unresectable or metastatic uveal melanoma Promotional launches and...
Immunocore Stories First Quarter 2022 Monetary Outcomes and Offers Enterprise Replace KIMMTRAK® (tebentafusp-tebn) authorised in the USA and European Union for the remedy of unresectable or metastatic uveal melanoma...